[18F]F-DOPA Imaging in Patients With Autonomic Failure
NCT04246437
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and/or glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g. caudal to rostral brainstem) give rise to distinct neurological phenotypes, including Parkinson's disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autonomic Failure
- Pure Autonomic Failure
- Parkinson Disease
- Multiple System Atrophy
- Dementia With Lewy Bodies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Daniel Claassen
- Last updated on ClinicalTrials.gov
- March 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.